Advertisement
OtherArticle

Ibrutinib blocks YAP1 activation and reverses BRAFi resistance in melanoma cells

Sean A Misek, Patrick A Newbury, Evgenii Chekalin, Shreya Paithankar, Andrea I Doseff, Bin Chen, Kathleen A Gallo and Richard R. Neubig
Molecular Pharmacology November 3, 2021, MOLPHARM-AR-2021-000331; DOI: https://doi.org/10.1124/molpharm.121.000331
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

OtherArticle

Ibrutinib re-sensitizes BRAFi-resistant melanoma

Sean A Misek, Patrick A Newbury, Evgenii Chekalin, Shreya Paithankar, Andrea I Doseff, Bin Chen, Kathleen A Gallo and Richard R. Neubig
Molecular Pharmacology November 3, 2021, MOLPHARM-AR-2021-000331; DOI: https://doi.org/10.1124/molpharm.121.000331
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement